Varex Imaging (VREX) Q1 2026 earnings review
Industrial Segments Soars, Cash Flow Sinks
Varex reported a mixed Q1. The headline numbers look solid: Revenue grew 5% YoY to $210M, driven by a 17% surge in the Industrial segment, and Non-GAAP EPS nearly doubled to $0.19 (vs. $0.10 restated). However, beneath the P&L improvements, the balance sheet took a hit. Operating cash flow swung to a negative $16M (burn), driven by a sharp increase in inventory. While the Cargo/Security business is accelerating, the core Medical segment remains stagnant (flat YoY). Guidance for Q2 suggests a deceleration in growth momentum.
🐂 Bull Case
The Industrial segment is no longer a side project; it grew 17% YoY to $65M, driven by cargo security system demand. This diversification reduces reliance on the cyclical medical market.
Despite inflation and tariff headwinds, Non-GAAP Gross Margin held steady at 34%, showing effective cost controls and a favorable product mix shift within Industrial.
🐻 Bear Case
Operating cash flow collapsed to -$16M (an outflow), compared to positive inflows in previous quarters. This was driven by a $29M sequential jump in inventories, raising concerns about working capital management.
The Medical segment (70% of revenue) was flat YoY at $145M. Despite management claims of strong CT demand, the numbers indicate the core business is not growing.
⚖️ Verdict: ⚪
Neutral. The execution in the Industrial segment is impressive, but the deterioration in cash flow and lack of growth in the core Medical business prevent a bullish rating. We need to see inventory convert to cash before upgrading.
Key Themes
Industrial & Cargo Security Acceleration
Industrial revenue is accelerating, up 17% YoY. This follows a 25% jump in 25Q4. The driver is the cargo security systems business, which is benefiting from global security needs. This segment is successfully offsetting the stagnation in Medical.
Inventory Bloat Eating Cash
Cash, cash equivalents, and marketable securities dropped from $155M at FY25 year-end to $126M in Q1. The culprit is working capital: Inventories swelled to $328M (+9.5% sequentially from $299M in just one quarter). Management attributes this to preparation for future demand, but it is currently a significant drag on liquidity.
China Market Stabilization
After significant volatility in FY25 due to tariff spikes (up to 145%) and investigations, the China situation appears to have stabilized, though not recovered to peak growth. The narrative has shifted from 'crisis management' to 'maintenance,' but the lack of Medical growth suggests China isn't providing a tailwind.
Earnings Quality Improvement
Despite the cash flow issues, GAAP Net Income turned positive ($2.3M) compared to a loss in the prior year period (-$0.3M). Non-GAAP EPS nearly doubled to $0.19 YoY (adjusted for new policy), showing that when product ships, the profitability profile is improving.
Medical Segment Stagnation
Medical revenue was $144.8M, virtually unchanged from $144.6M a year ago. Given that Medical accounts for nearly 70% of total sales, the inability to grow this segment despite easier comps from the destocking period in FY25 is a concern.
Other KPIs
Stable. Down slightly from 35% in 25Q4 but consistent with the year-ago period (34.5%). Indicates the company is managing tariff costs and mix shifts reasonably well.
Disciplined. Expenses decreased from $57.3M in the prior year period (-5%), primarily due to lower R&D spend ($21.7M vs $23.5M). This cost discipline contributed to the EPS beat.
Cash, cash equivalents, and marketable securities fell to $126M from $155M just three months ago. The primary driver was inventory investment.
Guidance
Decelerating. The midpoint ($217.5M) implies roughly 2% YoY growth compared to 25Q2 ($212.9M). This is a slowdown from the 5% growth seen in Q1 and the 11% growth in 25Q4.
Decelerating/Declining. The midpoint ($0.20) is below the $0.26 reported in 25Q2. This suggests that despite revenue stability, margin or tax headwinds may pressure the bottom line sequentially and YoY.
Key Questions
Inventory Build Justification
Inventories spiked by nearly $30M sequentially while revenue is guided to be relatively flat/up slightly in Q2. Is this build related to specific Industrial system orders that are delayed, or is it unintended buildup in Medical?
Medical Growth Disconnect
You mention 'demand for CT products remains strong,' yet Medical revenue was flat YoY. Are we seeing price erosion offsetting volume gains, or are other modalities (Fluoroscopy/Oncology) shrinking?
Q2 EPS Compression
Q2 EPS guidance midpoint ($0.20) is lower than 25Q2 actuals ($0.26) despite projected revenue growth. What is driving the implied margin contraction YoY?